You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

Investigational Drug Information for acoramidis


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for acoramidis?

acoramidis is an investigational drug.

There have been 6 clinical trials for acoramidis. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2020.

The most common disease conditions in clinical trials are Amyloidosis, Cardiomyopathies, and Amyloid Neuropathies, Familial. The leading clinical trial sponsors are Eidos Therapeutics, a BridgeBio company, Eidos Therapeutics, and Alexion Pharmaceuticals.

Recent Clinical Trials for acoramidis
TitleSponsorPhase
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR ParticipantsEidos Therapeutics, a BridgeBio companyPhase 3
Efficacy and Safety of Acoramidis (AG10) in Subjects With Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)Eidos TherapeuticsPhase 3
Efficacy and Safety of Acoramidis (AG10) in Subjects With Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)Eidos Therapeutics, a BridgeBio companyPhase 3

See all acoramidis clinical trials

Clinical Trial Summary for acoramidis

Top disease conditions for acoramidis
Top clinical trial sponsors for acoramidis

See all acoramidis clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.